Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3329)	7/13/2021 2:07:40 AM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

I am not sure which modality they will utilize, but I will note two things. Right now they have LepR agonist antibody in the clinic. LepR was also mentioned in this paper as one of the genetically validated common variant hits. I would expect perhaps a combo (multiple targets) approach is coming. 2. The recent deal with ALNY focused on its next-gen RNAi platform that specifically targets the CNS (and for the eye). If ALNY drug can get distributed to CNS where it needs to go and Abs can't, they will go with RNAi, and the profit sharing is not a relevant factor.